12,372 trials
Major Depressive Disorder
Primary: Change From Baseline to the End of Treatment (EOT) in the Montgomery Asberg Depression Rating Scale-10 (MADRS-10) Scores — -11.4; -13.9; -4.2; -4.7 score on a scale…
Ulcerative Colitis
Primary: Proportion of Subjects With Remission — 19; 13 Participants — p=>0.05
Infertility, Female
Primary: Rate of Good Birth Outcomes — 23; 29 Participants — p=0.404
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline for Mean Reflective Total Nasal Symptom Score (rTNSS) — -2.95; -3.13; -1.98 score on a scale
Metabolism and Nutrition Disorder · Obesity
Primary: Change From Randomisation to Week 68 in Body Weight (%) — -8.3; 6.5; -8.8; 6.1 Percentage point — p=<0.0001
Parenteral Nutrition-related Hepatitis
Primary: Disease Progression as Measured by Serum Levels of Hepatic Enzymes
HIV
Primary: Safety and Tolerability of Ibalizumab + OBR — 8; 9 participants
Human Influenza
Primary: Increase in Geometric Mean Titre Ratio, A/H1N1 Strain — 4.337; 4.702 Ratio of Day 0 and Day 21-28 titres
Actinic Keratoses
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 5; 44 percentage of participants — p=<0.0001
Actinic Keratosis
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 13; 54 percentage of participants — p=<0.0001
Obstructive Sleep Apnea Syndrome
Primary: Obstructive Apnea Hypopnea Index — 7.69; 6.33 events per hour
Pain Management
Primary: Adverse Events — 251 Participants
Episodic Migraine
Primary: Change From Baseline in Monthly Migraine Days at the Last Month (Month 3) of the Double-blind Treatment Period (DBTP) — -4.20; -4.79; -3.10 Migraine days/month — p=0.002
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Time to the Next COPD Exacerbation — 72; 58 days — p=0.764
Ulcerative Colitis
Primary: Percentage of Participants in Remission at Week 10 With Etrolizumab Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28949 Population — 11.1; 18.2…